Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis
- 25 July 1988
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 62 (3), B77-B81
- https://doi.org/10.1016/s0002-9149(88)80057-2
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Toxicity of oxidized low-density lipoprotein to cultured fibroblasts is selective for S phase of the cell cycleJournal of Cellular Physiology, 1987
- Effect of hypolipidemic drugs on the metabolism of lauric acid and dimethylaminoazobenzene by rat liver microsomesBiochemical Pharmacology, 1987
- PLATELET-DERIVED GROWTH FACTORAnnual Review of Medicine, 1987
- Probucol prevents lipid storage in macrophagesAtherosclerosis, 1986
- Probucol inhibits oxidative modification of low density lipoprotein.Journal of Clinical Investigation, 1986
- Atherosclerosis as an Inflammatory ProcessAnnals of the New York Academy of Sciences, 1985
- CHARACTERIZATION OF A LEUKOCYTE‐DERIVED ENDOGENOUS MEDIATOR RESPONSIBLE FOR INCREASED PLASMA FIBRINOGENAnnals of the New York Academy of Sciences, 1982
- The scavenger cell pathway for lipoprotein degradation: Specificity of the binding site that mediates the uptake of negatively‐charged LDL by macrophagesJournal of Supramolecular Structure, 1980
- Heberden oration 1978. Recent studies on the control of joint damage: the contribution of the Strangeways Research Laboratory.Annals Of The Rheumatic Diseases, 1979
- An overview of the biochemical pharmacology of probucolLipids, 1977